Immune alterations in acute bipolar depression

Acta Psychiatrica Scandinavica

Volumn 132, Issue 3, 2015, Pages 204-210

  Dickerson, F ^a   Katsafanas, E ^a   Schweinfurth, L A B ^a   Savage, C L G ^a   Stallings, C ^a   Origoni, A ^a   Khushalani, S ^a   Lillehoj, E ^b   Yolken, R ^c  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorder; Depression; Neuroimmunology

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN G ANTIBODY; PENTRAXIN 3; BIOLOGICAL MARKER; SERUM AMYLOID P;

ADULT; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CONTROLLED STUDY; ENDOGENOUS RETROVIRUS; FEMALE; FOLLOW UP; HERPESVIRIDAE; HOSPITALIZATION; HUMAN; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; MANIA; MASON-PFIZER MONKEY VIRUS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; TOXOPLASMA GONDII; YOUNG MANIA RATING SCALE; ACUTE DISEASE; BIPOLAR DISORDER; BLOOD; IMMUNOLOGY; IMMUNOMODULATION; MIDDLE AGED; PARASITOLOGY; VIROLOGY;

ACUTE DISEASE; ADULT; BIOMARKERS; BIPOLAR DISORDER; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROIMMUNOMODULATION; SERUM AMYLOID P-COMPONENT;

EID: 84938751026     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12451     Document Type: Article

References (46)

1. Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 2007;9:531-535.
2. Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unutzer J. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry 2007;68:1237-1245.
3. Network Pathway Analysis Subgroup of Psychiatric Genetics Consortium. Psychiatric genome-wide association study analyses implicate neuronal immune and histone pathways. Nat Neurosci 2015;18:199-209.
4. Anderson G, Maes M. Bipolar disorder: role of immune-inflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites. Curr Psychiatry Rep 2015;17:541.
5. Mesman E, Hillegers MH, Ambree O, Arolt V, Nolen WA, Drexhage HA. Monocyte activation, brain-derived neurotrophic factor (BDNF), and S100B in bipolar offspring: a follow-up study from adolescence into adulthood. Bipolar Disord 2015;17:39-49.
6. Barbosa IG, Machado-Vieira R, Soares JC, Teixeira AL. The immunology of bipolar disorder. NeuroImmunoModulation 2014;21:117-122.
7. Barbosa IG, Rocha NP, Assis F, Vieira EL, Soares JC, Bauer ME, et al. Monocyte and lymphocyte activation in bipolar disorder: a new piece in the puzzle of immune dysfunction in mood disorders. Int J Neuropsychopharmacol 2014;18:pii:pyu021.
8. Rege S, Hodgkinson SJ. Immune dysregulation and autoimmunity in bipolar disorder: synthesis of the evidence and its clinical application. Aust N Z J Psychiatry 2013;47:1136-1151.
9. Dargel AA, Godin O, Kapczinski F, Kupfer DJ, Leboyer M. C-reactive protein alterations in bipolar disorder: a meta-analysis. J Clin Psychiatry 2015;76:142-150.
10. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013;74:15-25.
11. Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 2013;47:1119-1133.
12. Ghoreschi K, Laurence A, Yang XP, Hirahara K, O'Shea JJ. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 2011;32:395-401.
13. Severance EG, Gressitt KL, Yang S, Stallings CR, Origoni AE, Vaughan C, et al. Seroreactive marker for inflammatory bowel disease and associations with antibodies to dietary proteins in bipolar disorder. Bipolar Disord 2014;16:230-240.
14. Dickerson F, Stallings C, Origoni A, Vaughan C, Katsafanas E, Khushalani S, et al. Antibodies to Toxoplasma gondii in individuals with mania. Bipolar Disord 2014;16:129-136.
15. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Markers of gluten sensitivity in acute mania: a longitudinal study. Psychiatry Res 2012;196:68-71.
16. Dickerson F, Stallings C, Origoni A, Vaughan C, Katsafanas E, Khushalani S, et al. A combined marker of inflammation in individuals with mania. PLoS ONE 2013;8:e73520.
17. Dickerson F, Stallings C, Origoni A, Katsafanas E, Schweinfurth LA, Savage CL, et al. Pentraxin 3 is reduced in bipolar disorder. Bipolar Disord 2015;17:409-414.
18. de Baumont A, Maschietto M, Lima L, Carraro DM, Olivieri EH, Fiorini A, et al. Innate immune response is differentially dysregulated between bipolar disease and schizophrenia. Schizophr Res 2015;161:215-221.
19. Foldager L, Kohler O, Steffensen R, Thiel S, Kristensen AS, Jensenius JC, et al. Bipolar and panic disorders may be associated with hereditary defects in the innate immune system. J Affect Disord 2014;164:148-154.
20. Oliveira J, Busson M, Etain B, Jamain S, Hamdani N, Boukouaci W, et al. Polymorphism of Toll-like receptor 4 gene in bipolar disorder. J Affect Disord 2014;152-154:395-402.
21. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009;70:1078-1090.
22. de Oliveira GS, Cereser KM, Fernandes BS, Kauer-Sant'anna M, Fries GR, Stertz L, et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res 2009;43:1171-1174.
23. Walz JC, Andreazza AC, Frey BN, Cacilhas AA, Cereser KM, Cunha AB, et al. Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder. Neurosci Lett 2007;415:87-89.
24. Drexhage RC, Knijff EM, Padmos RC, Heul-Nieuwenhuijzen L, Beumer W, Versnel MA, et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010;10:59-76.
25. Hope S, Melle I, Aukrust P, Steen NE, Birkenaes AB, Lorentzen S, et al. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord 2009;11:726-734.
26. Teixeira AL, de Souza RT, Zanetti MV, Brunoni AR, Busatto GF, Zarate CA Jr, et al. Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment. Hum Psychopharmacol 2015;30:52-56.
27. First M, Gibbon M, Spitzer RL, Williams JBW. Structured clinical interview for DSM-IV disorders, Non-Patient Edition. New York, NY: Biometrics Research, 1998.
28. First M, Gibbon M, Spitzer RL, Williams JBW. User's guide for the SCID-I, structured clinical interview for DSM IV axis I disorders. New York, NY: Biometrics Research, 1996.
29. Braveman PA, Cubbin C, Egerter S, Chideya S, Marchi KS, Metzler M, et al. Socioeconomic status in health research: one size does not fit all. JAMA 2005;294:2879-2888.
30. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310-319.
31. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
32. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-435.
33. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Psychol 1967;6:278-296.
34. Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Ruslanova I, Yolken RH. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch Gen Psychiatry 2003;60:466-472.
35. Dickerson F, Lillehoj E, Stallings C, Wiley M, Origoni A, Vaughan C, et al. Antibodies to retroviruses in recent onset psychosis and multi-episode schizophrenia. Schizophr Res 2012;138:198-205.
36. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yang S, et al. C-reactive protein is elevated in schizophrenia. Schizophr Res 2013;143:198-202.
37. Dickerson F, Boronow J, Stallings C, Origoni A, Yolken R. Toxoplasma gondii in individuals with schizophrenia: association with clinical and demographic factors and with mortality. Schizophr Bull 2007;33:737-740.
38. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:952-955.
39. Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005;3:1618-1627.
40. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr Res 2012;134:83-88.
41. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord 2013;150:456-459.
42. Daigo K, Mantovani A, Bottazzi B. The yin-yang of long pentraxin PTX3 in inflammation and immunity. Immunol Lett 2014;161:38-43.
43. Mancini RJ, Stutts L, Ryu KA, Tom JK, Esser-Kahn AP. Directing the immune system with chemical compounds. ACS Chem Biol 2014;9:1075-1085.
44. Mangeney M, de Parseval N, Thomas G, Heidmann T. The full-length envelope of an HERV-H human endogenous retrovirus has immunosuppressive properties. J Gen Virol 2001;82(Pt 10):2515-2518.
45. Michaud HA, Sengupta D, De Mulder M, Deeks SG, Martin JN, Kobie JJ, et al. Cutting edge: an antibody recognizing ancestral endogenous virus glycoproteins mediates antibody-dependent cellular cytotoxicity on HIV-1-infected cells. J Immunol 2014;193:1544-1548.
46. Kremer D, Forster M, Schichel T, Gottle P, Hartung HP, Perron H, et al. The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligo-dendroglial maturation blockade. Mult Scler 2014; doi: 10.1177/1352458514560926 [Epub ahead of print].